See the DrugPatentWatch profile for Ingrezza
What is Ingrezza primarily used for?
Ingrezza is prescribed to treat tardive dyskinesia, a movement disorder characterized by involuntary, repetitive movements. It is also indicated for treating chorea associated with Huntington's disease [1].
How does Ingrezza work?
Ingrezza functions by selectively inhibiting the vesicular monoamine transporter type 2 (VMAT2). This mechanism helps to reduce the release of dopamine, a neurotransmitter that is overactive in conditions like tardive dyskinesia [1].
Are there other medications for tardive dyskinesia?
Yes, there are other medications available for tardive dyskinesia. These often also target the VMAT2 pathway. Two other VMAT2 inhibitors, Austedo and Austedo XR, are also approved for this condition [2].
How do Ingrezza and Austedo compare?
Both Ingrezza and Austedo are VMAT2 inhibitors approved for tardive dyskinesia. Austedo and Austedo XR are also indicated for chorea associated with Huntington's disease, similar to Ingrezza [2]. The choice between them may depend on individual patient response, tolerability, and physician preference.
When does Ingrezza's patent protection expire?
Information regarding specific patent expiration dates for Ingrezza can be found on specialized patent tracking websites. For instance, DrugPatentWatch.com provides detailed patent timelines for many pharmaceuticals, including Ingrezza [3].
What are the potential side effects of Ingrezza?
Common side effects associated with Ingrezza include somnolence and potential for QT interval prolongation. It is important for patients to discuss any concerns about side effects with their healthcare provider [1].
What is the cost of Ingrezza?
The cost of Ingrezza can vary significantly based on insurance coverage, pharmacy, and dosage. Patients often inquire about cost-saving programs or patient assistance options when considering Ingrezza [4].